Inhibition of the norepinephrine transporter to treat neurogenic orthostatic hypotension: is this the end of the story?

Clin Auton Res. 2021 Dec;31(6):645-647. doi: 10.1007/s10286-021-00839-w.

Authors

Guillaume Lamotte¹, Patricio Millar Vernetti²

Affiliations

¹ Department of Neurology, University of Utah, Salt Lake City, UT, USA. guillaumelamotte14@gmail.com.
² Department of Neurology, Dysautonomia Center, NYU Langone Medical Center, New York, NY, USA.

PMID: 34757507
DOI: 10.1007/s10286-021-00839-w

No abstract available

Keywords: Ampreloxetine; Autonomic; Multiple system atrophy; Parkinson disease; Pure autonomic failure.

Publication types

Editorial
Comment

MeSH terms

Droxidopa* / therapeutic use
Humans
Hypotension, Orthostatic* / drug therapy
Norepinephrine
Norepinephrine Plasma Membrane Transport Proteins

Substances

Norepinephrine Plasma Membrane Transport Proteins
Droxidopa
Norepinephrine